Article

Characterizing Gene Therapy Medicinal Products Post-Marketing Safety Reports based on WHO Pharmacovigilance Database, VigiBase

2024-08-09

Abstract excerpt

<title>Abstract</title> <p><bold>Background</bold> Safety assessments of gene therapy medicinal products (GTMPs) require comprehensive data collection from a variety of sources to ensure thorough evaluation. This study aimed to analyze the characteristics of adverse event (AE) reports for GTMPs, dividing them into Solicited Reports (SRs) and Unsolicited Reports (USRs), and to provide insights for developing effec...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: c5e382ad-a1d6-5eeb-864b-fcc2bb44fe11
DOI: 10.21203/rs.3.rs-4705551/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Characterizing Gene Therapy Medicinal Products Post-Marketing Safety Reports based on WHO Pharmacovigilance Database, VigiBaseDOI 10.21203/rs.3.rs-4705551/v1Read

Analysis of the adverse effects of used clinical Antisense Oligonucleotide drugs in DMD patients based on the FAERS databaseSemantic proximity Read

A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for TivozanibSemantic proximity Read

Pharmacovigilance analysis of inclisiran:a real-world assessment based on the FAERS databaseSemantic proximity Read

Adverse drug reactions associated with the use of biological agentsSemantic proximity Read

Expanded Spectrum and Increased Incidence of Adverse Events Linked to COVID-19 Genetic Vaccines: New Concepts on Prophylactic Immuno-Gene Therapy, Iatrogenic Orphan Disease and Platform-Inherent ChallengesSemantic proximity Read

Safety assessment of S-1: Real-world adverse event analysis from the FAERS databaseSemantic proximity Read

Cross-Database Analysis of Fruquintinib-Associated adverse events: Insights from FAERS and VigiAccess databasesSemantic proximity Read

Gastrointestinal adverse events associated with Riociguat: A pharmacovigilance study based on FDA adverse event reporting systemSemantic proximity Read

Demographics, Overlap, and Latency of Severe Cutaneous Adverse Reactions in an FDA DatabaseSemantic proximity Read

Long-term follow-up after authorization of gene therapy: leveraging real-world dataSemantic proximity Read

A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) events for OsimertinibSemantic proximity Read

Real-World Data Analysis of Vascular and Lymphatic Adverse Events Associated with Anti-Tumor Angiogenesis Drugs: A WHO-VigiAccess StudySemantic proximity Read